The (Epi)Pen is Mightier Than the Sword
[by Howard Fencl, Hennes Communications] Is it something in the DNA of biopharma CEOs that lights up righteous indignation all over social media and focuses the media spotlight on their self-made crises? Not long ago, I wrote about Turing Pharmaceutical’s 5,000 percent price hike of the toxoplasmosis drug, Daraprim, and the clueless swagger of its […]